Clinical experience with N-acetylcarnosine use in patients with age-related cataract


  • N.V. Malachkova National Pirogov Memorial Medical University, Vinnytsia, Ukraine
  • Ye.L. Prus Vision Center “Optimal”, Vinnytsia, Ukraine
  • K.M. Radioha Vision Center “Optimal”, Vinnytsia, Ukraine



age-related cataract, achromatic visocontrastometry, lens, Lens Opacities Classification System III, antioxidants


Background. Cataract remains one of the most common diseases in the world leading to blindness. Pathological conditions associated with lens aging have long been known, including presbyopia and age-related cataract. That is why the World Health Organization supports the feasibility of further large-scale studies on the effectiveness of drugs for the prevention of cataract, especially with the use of antioxidants (2018). The aim of the study was to evaluate the effect of N-acetylcarnosine contained in Clarastill on the condition of the lens with long-term use (6 months) in patients with cataract. Materials and methods. The study lasted 6 months in two groups. The first (control) group included 10 patients (18 eyes) aged 65.3 ± 3.0 years, the second group — 20 individuals (37 eyes) aged 63.4 ± 5.0 years with a diagnosis of senile cataract. The study was conducted in accordance with the Declaration of Helsinki 1964. Patients in the first group did not receive any drops and were only monitored for the entire period. Patients in the second group received Clarastill twice daily (local instillations into the conjunctival sac) for 6 months. Results. It was recorded that in the group of patients who used N-acetylcarnosine, there was an improvement in visual acuity, results of achromatic visocontrastometry, Norn and Schirmer tests, as well as the condition of the lens according to the Lens Opacities Classification System III. Conclusions. Clarastill as a pharmaceutical product containing N-acetylcarnosine delays cataract progression and, in some cases, significantly restores lens transparency in the initial (early) stages of cataract formation and can potentially significantly delay surgery.


Нарушение зрения и слепота. 11 октября 2018 г. ВООЗ. Режим доступу:

Selin J.Z., Wolk A. et al. Are increased levels of systemic oxidative stress and inflammation associated with age-related cataract. Antioxidants and Redox Signaling. 2014. Vol. 21. P. 700-704.

Khan A., Petropoulos I.N., Ponirakis G., Malik R.A. Visual Complications in Diabetes Mellitus: Beyond Retinopathy. Diabetic Medicine. 2017. Vol. 34(4). P. 478-484.

Ashok K. Grover, Sue E. Samson. Antioxidants and vision health: facts and fiction. Molecular and Cellular Biochemistry. 2014. Vol. 388. P. 173-183.

Thrimawithana T.R., Bunt C.R. et al. Drug Delivery to the Lens for the Management of Cataracts. Advanced Drug Delivery Reviews. 2018. Vol. 15. P. 185-194.

Leo T. Chylack Jr, John K. Wolfe. The lens opacities classification system. Archives of ophthalmology. Arch. Ophthalmol. 1993 Jun. Vol. 111(6). Р. 831-6.

Mark A. Babizhayev, Johan Bours. et al. Revival of the Lens Transparency with N-Acetylcarnosine. Bentham Science Publishers. 2006.

Mark A. Babizhayev. Generation of reactive oxygen species in the anterior eye segment. Synergistic codrugs of N-acetylcarnosine lubricant eye drops and mitochondria-targeted antioxidant act as a po­werful therapeutic platform for the treatment of cataracts and primary open-angle glaucoma. 2016. DOI: 10.1016/j.bbacli.2016.04.004.

Чупров А.Д., Горбунов А.А., Николаева Ю.А. Исследование пространственной контрастной чувствительности при помощи программы «Зебра» для оценки качества зрения у пациентов после факоэмульсификации возрастной катаракты с имплантацией мультифокальной ИОЛ Lentis Comfort. Исследования в офтальмологии. 2012. Режим доступу:

Бикбулатова А.А. Контрастная чувствительность при односторонней гиперметропии высокой степени до и после рефракционной ленсэктомии с имплантацией ИОЛ. Новые технологии факоэмульсификации катаракты. 2011.





Exchange of Experience